Declarations. Conflict of Interest: Tunde Peto: Received grant support paid to institution from Boehringer Ingelheim; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Apellis, Bayer, Boehringer Ingelheim, Heidelberg, Novartis, OPTOS, Oxurion, Roche, and Zeiss. Stela Vujosevic: Consultant for AbbVie, Adverum, Annexon, Apellis, Bayer, Boehringer Ingelheim, Novartis, Roche, and Zeiss. Veeral Sheth: Consultant for Apellis, EyePoint, Genentech, IvericBio, Kriya Therapeutics, Novartis, Ocular Therapeutix, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity, and Vial; speaker for Genentech and IvericBio; contracted research for 4D Molecular Therapeutics, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Aviceda, Chengdu Kanghong, Eyebiotech, Eyepoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, IvericBio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocugen, OcuTerra, Olix, Opthea, Outlook, Oxular, Oxurion, Perfuse Therapeutics, Recens Medical, Regeneron Pharmaceuticals, RegenXBio, Rezolute, Roche, SalutarisMD, SamChungDang, Santen, Smilebiotek, Unity Biotechnology, and Vanotech. Amanda Downey: Employee of F. Hoffmann-La Roche Ltd. Kara Gibson: Employee and stockholder of Roche Products Ltd. Andreas Pollreisz: Consultant for Allergan, Bayer, Oertli Instruments, and Roche. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.